177 related articles for article (PubMed ID: 14599646)
1. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
Koury MJ; Newman JH; Murray JJ
Am J Med; 2003 Nov; 115(7):587-9. PubMed ID: 14599646
[No Abstract] [Full Text] [Related]
2. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
McPherson T; Cowen EW; McBurney E; Klion AD
Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches to therapy of hypereosinophilic syndromes.
Simon HU; Cools J
Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement.
Torres-Navarro I; Navarro-Mira MÁ; de Unamuno-Bustos B; Botella-Estrada R
J Dtsch Dermatol Ges; 2020 Apr; 18(4):378-380. PubMed ID: 32291914
[No Abstract] [Full Text] [Related]
5. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
Tan D; Hwang W; Ng HJ; Goh YT; Tan P
Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
[TBL] [Abstract][Full Text] [Related]
7. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
[TBL] [Abstract][Full Text] [Related]
8. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib.
Ikezoe T; Togitani K; Tasaka T; Nishioka C; Yokoyama A
Leuk Res; 2010 Aug; 34(8):e200-1. PubMed ID: 20303172
[No Abstract] [Full Text] [Related]
10. Hypereosinophilic syndrome.
Roufosse FE; Goldman M; Cogan E
N Engl J Med; 2003 Jun; 348(26):2687; author reply 2687. PubMed ID: 12826646
[No Abstract] [Full Text] [Related]
11. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
[TBL] [Abstract][Full Text] [Related]
12. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
[TBL] [Abstract][Full Text] [Related]
13. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor.
Ascione L; De Michele M; Accadia M; Spadaro P; Rumolo S; Tuccillo B
Eur J Echocardiogr; 2004 Oct; 5(5):386-90. PubMed ID: 15341874
[TBL] [Abstract][Full Text] [Related]
14. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis.
Ishii Y; Ito Y; Kuriyama Y; Tauchi T; Ohyashiki K
Leuk Res; 2004 May; 28 Suppl 1():S79-80. PubMed ID: 15036947
[No Abstract] [Full Text] [Related]
16. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib].
Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA
Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hypereosinophilic syndrome with imatinib mesilate.
Gleich GJ; Leiferman KM; Pardanani A; Tefferi A; Butterfield JH
Lancet; 2002 May; 359(9317):1577-8. PubMed ID: 12047970
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
Onitilo AA; Kio EA; Singh AK; Lazarchick J
Leuk Lymphoma; 2005 Nov; 46(11):1667-70. PubMed ID: 16236620
[TBL] [Abstract][Full Text] [Related]
19. Images in cardiology: Hypereosinophilic syndrome and effect of imatinib mesylate.
Jacob S; Kovacs RJ
Clin Cardiol; 2005 Apr; 28(4):188. PubMed ID: 15869052
[No Abstract] [Full Text] [Related]
20. Imatinib-responsive hypereosinophilic syndrome.
Robyn J
Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
[No Abstract] [Full Text] [Related]
[Next] [New Search]
